| ARDS during NR | No ARDS during NR | Odd ratio | 95% CI | P value |
---|---|---|---|---|---|
Age | 45.99 ± 1.79 | 45.38 ± 2.51 |  |  | 0.84 |
Male | 20 (52.6%) | 13 (39.4%) | 1.71 | 0.66-4.40 | 0.27 |
AML | 17 (44.7%) | 18 (54.5%) | 0.68 | 0.26-1.72 | 0.41 |
   ALL | 12 (31.6%) | 10 (30.3%) | 1.06 | 0.39-2.91 | 0.91 |
   Relapsed maligancy | 10 (26.3%) | 7 (21.2%) | 1.33 | 0.44-3.99 | 0.62 |
   Time from diagnosis, days | 244 ± 98.7 | 140 ± 56.8 |  |  | 0.38 |
   Anthracycline treatment | 20 (52.6%) | 18 (54.5%) | 0.93 | 0.36-2.36 | 0.87 |
   Cyclophosphamide treatment | 9 (23.7%) | 5 (15.2%) | 1.74 | 0.52-5.83 | 0.37 |
   Methotrexate treatment | 6 (15.8%) | 3 (9.1%) | 1.88 | 0.43-8.12 | 0.49 |
   Total chemotherapy times | 2.79 ± 0.27 | 2.36 ± 0.25 |  |  | 0.26 |
   Total chemotherapy times ≥3 times | 20 (52.6%) | 14 (42.4%) | 1.51 | 0.59-3.86 | 0.39 |
   Previous history of HSCT | 8 (21.1%) | 5 (15.2%) | 1.88 | 0.43-8.18 | 0.52 |
   Time between chemotherapy and onset of neutropenia | 3.45 ± 0.69 | 2.18 ± 0.65 |  |  | 0.19 |
   Time between chemotherapy and onset of neutropenia >10 days | 3 (7.9%) | 1 (3.0%) | 2.74 | 0.27-27.73 | 0.62 |
   Neutropenia duration, days | 22.4 ± 2.3 | 22.7 ± 2.4 |  |  | 0.94 |
   Neutropenia duration >10 days | 34 (89.5%) | 26 (78.8%) | 2.29 | 0.61-8.66 | 0.22 |
   Platelet transfusion during neutropenia | 38 (100%) | 32 (97%) |  |  | 0.47 |
   Plasma transfusion during neutropenia | 33 (86.8%) | 26 (78.8%) | 1.78 | 0.51-6.25 | 0.37 |
   Pneumonia during neutropenia | 32 (84.2%) | 13 (39.4%) | 8.21 | 2.68-25.07 | < 0.001 |
   RRT during neutropenia | 13 (34.2%) | 8 (24.2%) | 1.63 | 0.57-4.60 | 0.36 |
   ICU admission for respiratory failure | 25 (65.8%) | 10 (30.3%) | 4.42 | 1.63-12.03 | 0.003 |
   Mechanical ventilator therapy | 34 (89.5%) | 19 (57.6%) | 6.26 | 1.80-21.75 | 0.002 |
   In-ICU mortality | 33 (86.8%) | 17 (51.5%) |  |  | < 0.001 |